RVX Stock Overview
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Resverlogix Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.055 |
52 Week High | CA$0.26 |
52 Week Low | CA$0.055 |
Beta | 0.78 |
1 Month Change | -8.33% |
3 Month Change | -21.43% |
1 Year Change | -62.07% |
3 Year Change | -93.53% |
5 Year Change | -98.39% |
Change since IPO | -96.45% |
Recent News & Updates
Shareholder Returns
RVX | CA Biotechs | CA Market | |
---|---|---|---|
7D | 0% | 1.4% | 0.4% |
1Y | -62.1% | -26.0% | 9.0% |
Return vs Industry: RVX underperformed the Canadian Biotechs industry which returned -26% over the past year.
Return vs Market: RVX underperformed the Canadian Market which returned 9% over the past year.
Price Volatility
RVX volatility | |
---|---|
RVX Average Weekly Movement | 12.7% |
Biotechs Industry Average Movement | 12.4% |
Market Average Movement | 8.5% |
10% most volatile stocks in CA Market | 18.4% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: RVX's share price has been volatile over the past 3 months.
Volatility Over Time: RVX's weekly volatility (13%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 19 | Don McCaffrey | https://www.resverlogix.com |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications.
Resverlogix Corp. Fundamentals Summary
RVX fundamental statistics | |
---|---|
Market cap | CA$15.10m |
Earnings (TTM) | -CA$17.36m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs RVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RVX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$12.82m |
Earnings | -US$12.82m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.047 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -97.4% |
How did RVX perform over the long term?
See historical performance and comparison